Adalimumab-adaz Injection shortage
To Be Discontinued 5 presentations · 1 manufacturers · first FDA posting 2026-01-13 · last update 2026-01-13
Manufacturers: Sandoz Inc.
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-36) | Sandoz Inc. | To Be Discontinued | — | Equivalent Sandoz format is available. | Posted 01/13/2026 Updated 01/13/2026 Discontinued 01/13/2026 |
| Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-68) | Sandoz Inc. | To Be Discontinued | — | Equivalent Sandoz format is available. | Posted 01/13/2026 Updated 01/13/2026 Discontinued 01/13/2026 |
| Hyrimoz, Injection, 40 mg/.4 mL (NDC 61314-473-64) | Sandoz Inc. | To Be Discontinued | — | Equivalent Sandoz format is available. | Posted 01/13/2026 Updated 01/13/2026 Discontinued 01/13/2026 |
| Hyrimoz, Injection, Kit (NDC 61314-517-36) | Sandoz Inc. | To Be Discontinued | — | Equivalent Sandoz format is available. | Posted 01/13/2026 Updated 01/13/2026 Discontinued 01/13/2026 |
| Hyrimoz, Injection, Kit (NDC 61314-531-64) | Sandoz Inc. | To Be Discontinued | — | Equivalent Sandoz format is available. | Posted 01/13/2026 Updated 01/13/2026 Discontinued 01/13/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)